It has been reported that the new type of HDACi chidamide (CDM) can achieve a complete remission in a relapsed and refractory AML patient with MLL-AF9 translocation [14], indicating that CDM may be a good candidate for AML treatment. The gene discussed is KMT2A; the disease is acute myeloid leukemia.